Psoriatic arthritis secondary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Essential measures for the secondary prevention of psoriatic arthritis include calcium and vitamin D supplementation to prevent drug associated osteoporosis. To decrease the risk of cardiovascular complications and to prevent recurrent episodes effective measures include exercise, smoking cessation, and dietary control. | Essential measures for the secondary [[Prevention (medical)|prevention]] of psoriatic arthritis include [[calcium]] and [[vitamin D]] supplementation to prevent drug associated [[osteoporosis]]. To decrease the risk of [[cardiovascular]] complications and to prevent recurrent episodes effective measures include [[Physical exercise|exercise]], [[smoking]] cessation, and dietary control. | ||
== Secondary prevention == | == Secondary prevention == | ||
* The following measures may be helpful for the secondary prevention of psoriatic arthritis: | * The following measures may be helpful for the secondary [[Prevention (medical)|prevention]] of psoriatic arthritis: | ||
** Protection of bone is essential due to the prolonged use of glucocorticoids and DMARDs to prevent drug induced osteoporosis. | ** Protection of [[bone]] is essential due to the prolonged use of [[glucocorticoids]] and [[Disease-modifying antirheumatic drug|DMARDs]] to prevent drug induced [[osteoporosis]]. | ||
**Supplemental intake of calcium 1000 to 1200 mg/day and vitamin D 600 to 800 IU/day is recommended for patients using prolonged glucocorticoids.<ref name="pmid28585373">{{cite journal |vauthors=Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Robinson AB, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, McAlindon T |title=2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis |journal=Arthritis Rheumatol |volume=69 |issue=8 |pages=1521–1537 |date=August 2017 |pmid=28585373 |doi=10.1002/art.40137 |url=}}</ref> | **Supplemental intake of [[calcium]] 1000 to 1200 mg/day and [[vitamin D]] 600 to 800 IU/day is recommended for patients using prolonged [[glucocorticoids]].<ref name="pmid28585373">{{cite journal |vauthors=Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Robinson AB, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, McAlindon T |title=2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis |journal=Arthritis Rheumatol |volume=69 |issue=8 |pages=1521–1537 |date=August 2017 |pmid=28585373 |doi=10.1002/art.40137 |url=}}</ref> | ||
* Patients are monitored regularly for [[disease]] activity, [[:Category:Drugs|drug]] efficacy, [[Adverse effect (medicine)|adverse effects]] and associated [[Comorbidity|comorbid conditions]].<ref name="pmid14730596">{{cite journal |vauthors=Gladman DD, Helliwell P, Mease PJ, Nash P, Ritchlin C, Taylor W |title=Assessment of patients with psoriatic arthritis: a review of currently available measures |journal=Arthritis Rheum. |volume=50 |issue=1 |pages=24–35 |date=January 2004 |pmid=14730596 |doi=10.1002/art.11417 |url=}}</ref> | * Patients are monitored regularly for [[disease]] activity, [[:Category:Drugs|drug]] efficacy, [[Adverse effect (medicine)|adverse effects]] and associated [[Comorbidity|comorbid conditions]].<ref name="pmid14730596">{{cite journal |vauthors=Gladman DD, Helliwell P, Mease PJ, Nash P, Ritchlin C, Taylor W |title=Assessment of patients with psoriatic arthritis: a review of currently available measures |journal=Arthritis Rheum. |volume=50 |issue=1 |pages=24–35 |date=January 2004 |pmid=14730596 |doi=10.1002/art.11417 |url=}}</ref> | ||
* The following measures are helpful to prevent cardiovascular complications associated with psoriatic arthritis.<ref name="pmid27697765">{{cite journal |vauthors=Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ, Kvien TK, Dougados M, Radner H, Atzeni F, Primdahl J, Södergren A, Wallberg Jonsson S, van Rompay J, Zabalan C, Pedersen TR, Jacobsson L, de Vlam K, Gonzalez-Gay MA, Semb AG, Kitas GD, Smulders YM, Szekanecz Z, Sattar N, Symmons DP, Nurmohamed MT |title=EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update |journal=Ann. Rheum. Dis. |volume=76 |issue=1 |pages=17–28 |date=January 2017 |pmid=27697765 |doi=10.1136/annrheumdis-2016-209775 |url=}}</ref> | * The following measures are helpful to prevent [[cardiovascular]] complications associated with psoriatic arthritis.<ref name="pmid27697765">{{cite journal |vauthors=Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ, Kvien TK, Dougados M, Radner H, Atzeni F, Primdahl J, Södergren A, Wallberg Jonsson S, van Rompay J, Zabalan C, Pedersen TR, Jacobsson L, de Vlam K, Gonzalez-Gay MA, Semb AG, Kitas GD, Smulders YM, Szekanecz Z, Sattar N, Symmons DP, Nurmohamed MT |title=EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update |journal=Ann. Rheum. Dis. |volume=76 |issue=1 |pages=17–28 |date=January 2017 |pmid=27697765 |doi=10.1136/annrheumdis-2016-209775 |url=}}</ref> | ||
**Smoking cessation | **[[Smoking]] cessation | ||
**Dietary control to prevent hyperlipidemia, hypertension, and diabetes mellitus. | **Dietary control to prevent [[Hyperlipidemia (patient information)|hyperlipidemia]], [[hypertension]], and [[diabetes mellitus]]. | ||
**Exercise | **[[Physical exercise|Exercise]] | ||
**Patient education | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Latest revision as of 14:40, 16 May 2018
|
Psoriatic arthritis Microchapters | |
|
Diagnosis | |
|---|---|
|
Treatment | |
|
Case Studies | |
|
Psoriatic arthritis secondary prevention On the Web | |
|
American Roentgen Ray Society Images of Psoriatic arthritis secondary prevention | |
|
Risk calculators and risk factors for Psoriatic arthritis secondary prevention | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chandrakala Yannam, MD [2]
Overview
Essential measures for the secondary prevention of psoriatic arthritis include calcium and vitamin D supplementation to prevent drug associated osteoporosis. To decrease the risk of cardiovascular complications and to prevent recurrent episodes effective measures include exercise, smoking cessation, and dietary control.
Secondary prevention
- The following measures may be helpful for the secondary prevention of psoriatic arthritis:
- Protection of bone is essential due to the prolonged use of glucocorticoids and DMARDs to prevent drug induced osteoporosis.
- Supplemental intake of calcium 1000 to 1200 mg/day and vitamin D 600 to 800 IU/day is recommended for patients using prolonged glucocorticoids.[1]
- Patients are monitored regularly for disease activity, drug efficacy, adverse effects and associated comorbid conditions.[2]
- The following measures are helpful to prevent cardiovascular complications associated with psoriatic arthritis.[3]
- Smoking cessation
- Dietary control to prevent hyperlipidemia, hypertension, and diabetes mellitus.
- Exercise
- Patient education
References
- ↑ Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, Humphrey MB, Lane NE, Magrey M, Miller M, Morrison L, Rao M, Robinson AB, Saha S, Wolver S, Bannuru RR, Vaysbrot E, Osani M, Turgunbaev M, Miller AS, McAlindon T (August 2017). "2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis". Arthritis Rheumatol. 69 (8): 1521–1537. doi:10.1002/art.40137. PMID 28585373.
- ↑ Gladman DD, Helliwell P, Mease PJ, Nash P, Ritchlin C, Taylor W (January 2004). "Assessment of patients with psoriatic arthritis: a review of currently available measures". Arthritis Rheum. 50 (1): 24–35. doi:10.1002/art.11417. PMID 14730596.
- ↑ Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ, Kvien TK, Dougados M, Radner H, Atzeni F, Primdahl J, Södergren A, Wallberg Jonsson S, van Rompay J, Zabalan C, Pedersen TR, Jacobsson L, de Vlam K, Gonzalez-Gay MA, Semb AG, Kitas GD, Smulders YM, Szekanecz Z, Sattar N, Symmons DP, Nurmohamed MT (January 2017). "EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update". Ann. Rheum. Dis. 76 (1): 17–28. doi:10.1136/annrheumdis-2016-209775. PMID 27697765.